Skip to main content
. 2023 Oct 30;9(11):e21486. doi: 10.1016/j.heliyon.2023.e21486

Fig. 4.

Fig. 4

MAP30 disrupts EBV genome maintenance and blocks cell proliferation of EBV-associated neoplastic cells A-B) Cells derived from LCL1 or AKATA were treated with 10, 50, or 100 ng/mL of rMAP30 or a mutant, while cells treated with 100 ng/mL of BSA were used as the control group. EBV genome accumulation in each sample was determined by qPCR and the amount of detected EBV DNA in the control group was set to 1. The EBV genome accumulation in each drug treated sample was calculated as the relative detected signal to the control group. The immune blots for EBNA1 and actin control are also shown. C-D) Two LCLs (LCL1 and LCL2) and two EBV(+) BL cell lines (AKATA and CCL87) were used to perform a cell proliferation assay. Two EBV-negative BL cell lines, BJAB and AKATA(−), were used as controls. Cells treated with 100 ng/mL of rMAP30, mutants, or control BSA were counted 0,1, 3, 5, 7, and 9 days after treatments.